Category: Legislative

A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.

340B health centers and other providers “are reporting that

Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats. Its numerous drug pricing provisions will likely undergo changes prior to

Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.

“By empowering Medicare

A GOP U.S. Senator who has been active on 340B matters for decades last week asked President Biden’s pick to be the U.S. Health and Human Services Department’s top lawyer if HHS could be doing more to protect the 340B

Efforts to pass federal drug pricing legislation, pronounced dead by many last week, arose in time for Halloween.

Liberal and conservative congressional Democrats and the White House reportedly are still trying to strike a deal centered on letting Medicare negotiate

Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

BI is the seventh manufacturer to

U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

The Democratic-controlled Senate Appropriations Committee praised the U.S. Health Resources and Services Administration (HRSA) for its actions

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.

Kalderos has created a service called 340B